Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

28.70 +0.88 (+3.16%)
Streaming Delayed Price Updated: 10:21 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Assembly Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces Upcoming Investor Conference Participation
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – 
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces $12.6 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.